Blueprint Genetics Whole Exome Sequencing

Sep 20, 2017

Blueprint Genetics is now offering whole-exome sequencing to customers in the US. The assay has a minimum mean coverage of 100-fold. On average, 98.9 percent of gene-coding regions, captured with Agilent SureSelect V6, are covered at least 15-fold. The company confirms all clinically relevant variants by Sanger sequencing and its interpretation team includes clinical experts. Turnaround time for the assay, which comes in different versions, is six to nine weeks.

More Like This

May 17, 2018

Precipio KRAS Liquid Biopsy Kits for Pancreatic Cancer

Precipio has launched two new research-use only ICEme kits for the detection of mutations in KRAS Exons 2 and 3 in pancreatic cancer. The kits use the company's proprietary ICE-COLD PCR liquid biopsy technology and are available for both qPCR and Sanger sequencing platforms. According to Precipio, its non-invasive, low-cost enrichment technology is well-suited for laboratories developing screening and monitoring tests. The kits will be priced at approximately $100 per specimen.

May 16, 2018

Veracyte Afirma Xpression Atlas

Veracyte has launched its Afirma Xpression Atlas test for thyroid cancer. The test uses RNA sequencing to analyze 761 DNA variants and 130 RNA fusions in over 500 genes that have been linked to thyroid cancer. The test's aim is to provide information to help clinicians make surgery and treatment decisions for patients who have thyroid nodules.

May 15, 2018

Invivoscribe LymphoTrack Dx TRB Assay

InvivoScribe Technologies has released its LymphoTrack Dx TRB Assay for the Illumina MiSeq platform, a CE-marked next-generation sequencing kit for in vitro diagnostic use. The assay completes the menu of Invivoscribe's CE-marked clonality assays on the MiSeq, enabling small and large laboratories to identify and track clonal rearrangements.

May 14, 2018

Interpace Diagnostics ThyGeNext

Interpace Diagnostics said it is launching ThyGenNext, a mutational panel for indeterminate thyorid nodules, at the American Association of Clinical Endocrinologists annual meeting this week. ThyGeNext builds on the company's ThyGenX panel (launched in August 2014) by adding numerous molecular markers, gene mutations, and RNA fusions, resulting in a more comprehensive set of indicators to identify malignant or benign nodules and ascertain aggressiveness and other characteristics. Specifically, it uses next-generation sequencing to identify more than 150 genetic alterations assciated with papillary and follicular thyroid carcinomas, the two most common forms of thyroid cancer.

May 14, 2018

Oncimmune EarlyCDT-Liver

Oncimmune launched the EarlyCDT-Liver test for hepatocellular carcinoma carcinoma in the US. The test has a specificity of 97 percent and is the second test launched by Oncimmune based on the EarlyCDT technology. EarlyCDT-Liver is a simple blood test and complementary to imaging-based testing. It can aid in stratifying high-risk patients whose diagnosis is indeterminate following ultrasound and CT or MRI. It can also aid in the risk assessment and early detection of HCC in high-risk patients with hepatic lesions less than 1 cm, Oncimmune said. The company has begun CE marking for a kit version of the test, which is expected to be completed by the end of Q1 2019. 

May 14, 2018

Bioprognos OncoCUP Dx

Spanish biotech firm Bioprognosis introduced a new version of its OncoCUP Dx, a noninvasive test for identifying cancers of unknown primary diagnosis. The test was developed and tested "in collaboration with few quick diagnosis units," an outpatient model for diagnostic workups that are used in Europe. QDUs are an alternative to hospitallizations and are designed to reduce delays in diagnosing potentially severe diseases. Among the cancers that OncoCUP Dx can identify are bladder cancer, breast cancer, colorectal cancer, liver cancer, and non-small cell lung cancer, Bioprognosis said. 


May 10, 2018

Beckman Coulter DxH 500 Software

Beckman Coulter has launched software to support new and exisiting DxH 500 hematology analyzers. The version 2 software upgrade allows small-volume clinical labs to access a proprietary dynamic-gating method for improve flagging, a quality control menu, and other things. The improvements allow labs to deliver fast, accurate results to physicians and patients with greater efficiency, Beckman Coulter said. 

May 09, 2018

Karius NGS Pathogen Test

Karius has launched a quantitative version of its next-generation sequencing-based test that identifies microbial cell-free DNA in blood. According to the company, the test can identify DNA from more than 1,000 pathogens including bacteria, DNA viruses, fungi, mold, and protozoa.

May 08, 2018

Intermountain Healthcare RxMatch Comprehensive Panel

Intermountain Precision Genomics Core Laboratory said its RxMatch Comprehensive Panel has expanded to 97 gene targets from 36. Originally launched last September as an anti-depressent panel, it now includes opioids, statins, immunosuppresants, anti-depressants, and others. Patients provide a DNA sample with a cheek swab collected in a physician's office. Results are available within about a week. Intermountain Precision Genomics Core Laboratory is part of Intermountain Healthcare.

May 02, 2018


Predicine has launched a new liquid biopsy panel called PredicineATLAS, which covers 600 genes and offers a readout of patients tumor mutational burden to help inform and assess immuno-oncology treatment.

The assay will be available first for research use only though an early access program, but the company aims to at some point add a CLIA-certified version as well.

May 01, 2018

Beckman Coulter's DxH 900

Beckman Coulter has commercially launched its DxH 900 hematology analyzer. The new instrument is aimed at mid- to high-volume clinical labs performing complete blood count and white blood cell differential tests. The firm said the DxH 900 offers high-resolution analysis of cells in their near-native states, providing a precise cellular assessment for red blood cell, platelet, and white blood cell test results on the first pass. 

The DxH 900 is now available for sale in Europe, the US, Canada, Australia, and New Zealand. 

Beckman Coulter, which is owned by Danaher, said the analyzer is a complement to its DxH 520 system.

Apr 30, 2018

Streck, Diesse Diagnostica Cube 30 Touch

Streck and Diesse Diagnostica have launched the Cube 30 Touch, an automated instrument for high-volume erythrocyte sedimentation rate testing in EDTA tubes. Streck said it is the exclusive distributor of the Cube 30 Touch in the US and Canada. The instrument produces ESR results directly from EDTA tubes without consuming the patient sample. It is also compatible with standard 4.0 mL K2EDTA tubes. Results can be achieved in 20 minutes. 

Apr 26, 2018

Agilent In Situ Hybridization Probes

Agilent Technologies introduced a number of in situ hybridization probes, including the EBER RNA CISH, Kappa, and Lambda mRNA CISH probes for Dako Omnis. Additionally, a manual IQFISH panel for lymphoma was launched following its CE marking. 

The EBER RNA CISH, Kappa, and Lambda mRNA CISH releases increase the diagnostic capabilities of the Dako Omnis instrument, which can now be used to simultaneously run tests involving CISH, FISH, and immunohistochemistry. Meanwhile, the IQFISH panel is a set of oligonucleotide-based FISH probes for detecting rearrangements involving the MYC, CBL2, BCL6, MALT1, CCND1, and IGH genes. The probes are for use on formalin-fixed, paraffin-embedded tissue sections, Agilent said, adding they are available in break-apart and dual-fusion methodologies.

Apr 25, 2018

HiberGene HG Pneumo/Meningo Combo

HiberGene has launched the HG Pneumo/Meningo Combo test for the rapid detection of meningococcal and pneumococccal meningitis. The loop-mediated isothermal amplification-based test covers up to 90 percent of cases of bacterial meningitis and provides results in less than one hour, compared to traditional microbiological methods which can take between 24 and 48 hours, the company said. Samples are incubated and read on HiberGene's HG Swift instrument. 

Apr 23, 2018

Qiagen QiaStat-Dx

Qiagen announced the European launch of the QiaStat-Dx platform during the European Congress of Clinical Microbiology and Infectious Diseases in Madrid. The company also launched the first test on the system, a 21-pathogen respiratory panel. QiaStat-Dx is a fully integrated and automated molecular testing system based on real-time PCR. It can detect up to 48 viral and bacterial targets simultaneously, enabled by microfluidic test casettes coupled with a six-wavelength optical sensor. There are also plans for the instrument to run immunoassays based on time-resolved fluorescence detection. The system, previously developed by StatDx as the DiagCore, received CE marking in January, prior to Qiagen's acquisition of StatDx.

Sponsored by
Thermo Fisher Scientific

In this webinar, the third in the “New Frontiers in Liquid Biopsy Research” series, Dr. Liya Xu of the University of Southern California Michelson Center for Convergent Biosciences will discuss her team’s work using liquid biopsy technology for breast cancer research.


This webinar will discuss how Sanofi used literature mining to annotate the association of human leukocyte antigen (HLA) alleles with diseases and drug hypersensitivity as part of a multiple sclerosis (MS) biomarker discovery project.


This webinar will discuss an effort underway at the University of North Carolina Medical Center's to overcome limitations in the hematological genomic testing workflow with artificial intelligence (AI) from Sophia Genetics.


This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.